Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Octapharma AG, headquartered in Switzerland (CH), is a leading player in the pharmaceutical preparation manufacturing industry. Founded in 1983, the company has established a strong presence in Europe, North America, and Asia, focusing on the development and production of human proteins derived from human plasma and recombinant technologies.
Specialising in therapeutic areas such as immunology, haematology, and critical care, Octapharma is renowned for its high-quality products, including immunoglobulins, coagulation factors, and albumin. The company’s commitment to innovation and patient care has positioned it as a trusted provider in the global market, with notable achievements in expanding its product portfolio and enhancing patient outcomes. With a dedication to excellence, Octapharma continues to set benchmarks in the pharmaceutical industry.
+10 vs industry average
Octapharma’s score of 52 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Octapharma, a pharmaceutical preparation manufacturing company headquartered in CH, reported its 2024 emissions at approximately 351.4 million kg CO2e. This total comprises Scope 1 emissions of 24.9 million kg CO2e, Scope 2 market-based emissions of 29.0 million kg CO2e, and various Scope 3 emissions. Key Scope 3 contributors include purchased goods and services at 102.3 million kg CO2e, capital goods at 93.5 million kg CO2e, and upstream transportation and distribution at 45.8 million kg CO2e.
In 2023, Octapharma's total emissions were approximately 330.8 million kg CO2e. This included Scope 1 emissions of 27.1 million kg CO2e, Scope 2 market-based emissions of 30.8 million kg CO2e, and Scope 3 emissions such as purchased goods and services at 93.1 million kg CO2e and capital goods at 72.0 million kg CO2e.
Octapharma is committed to achieving Net Zero emissions by 2050 across all scopes. The company has already achieved a 22% reduction in its overall emissions since 2019 and aims for a 30% reduction by 2028.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more